middle.news
How Will Mesoblast Capitalize on Ryoncil’s FDA Approval Amid $102M Loss?
3:37am on Saturday 30th of August, 2025 AEST
•
Healthcare
Read Story
How Will Mesoblast Capitalize on Ryoncil’s FDA Approval Amid $102M Loss?
3:37am on Saturday 30th of August, 2025 AEST
Key Points
FDA approval and US launch of Ryoncil for pediatric SR-aGVHD
FY2025 net loss of $102.1 million amid ongoing operating expenses
Strong cash position with $161.6 million reserves
Strategic partnerships with Grünenthal, JCR, Takeda, and Tasly
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
MESOBLAST (ASX:MSB)
OPEN ARTICLE